Journal Article

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis

Bandelow, Borwin, Strawbridge, Rebecca, Patrick, Fiona, Carter, Ben, Young, Allan H., Mantingh, Tim, de Angel, Valeria, Tsapekos, Dimosthenis, Taylor, Rachael, Nikolova, Viktoriya L., Marwood, Lindsey, Cleare, Anthony J.

2019

Overview

Depression is considered to have the highest disability burden of all conditions. Although treatment-resistant depression (TRD) is a key contributor to that burden, there is little understanding of the best treatment approaches for it and specifically the effectiveness of available augmentation approaches.AimsWe conducted a systematic review and meta-analysis to search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD. Participants with TRD (defined as insufficient response to at least two antidepressants) were randomised to at least one augmentation treatment in the trial. Pre-post analysis assessed treatment effectiveness, providing an effect size (ES) independent of comparator interventions. Of 28 trials, 3 investigated psychological treatments and 25 examined pharmacological interventions. Pre-post analyses demonstrated N-methyl-d-aspartate-targeting drugs to have the highest ES (ES = 1.48, 95% CI 1.25-1.71). Other than aripiprazole (four studies, ES = 1.33, 95% CI 1.23-1.44) and lithium (three studies, ES = 1.00, 95% CI 0.81-1.20), treatments were each investigated in less than three studies. Overall, pharmacological (ES = 1.19, 95% CI 1.80-1.30) and psychological (ES = 1.43, 95% CI 0.50-2.36) therapies yielded higher ESs than pill placebo (ES = 0.78, 95% CI 0.66-0.91) and psychological control (ES = 0.94, 95% CI 0.36-1.52). Despite being used widely in clinical practice, the evidence for augmentation treatments in TRD is sparse. Although pre-post meta-analyses are limited by the absence of direct comparison, this work finds promising evidence across treatment modalities.Declaration of interestIn the past 3 years, A.H.Y. received honoraria for speaking from AstraZeneca, Lundbeck, Eli Lilly and Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion and Janssen; and research grant support from Janssen. In the past 3 years, A.J.C. received honoraria for speaking from AstraZeneca and Lundbeck; honoraria for consulting with Allergan, Janssen, Livanova, Lundbeck and Sandoz; support for conference attendance from Janssen; and research grant support from Lundbeck. B.B. has recently been (soon to be) on the speakers/advisory board for Hexal, Lilly, Lundbeck, Mundipharma, Pfizer, and Servier. No other conflicts of interest.

• Publisher: Cambridge University Press
• Subject: Adjuvant therapy / Analysis / Antidepressants / Antidepressive Agents - therapeutic use / Antipsychotics / Aripiprazole / Augmentation / Clinical medicine / Clinical trials / Conflicts of interest / Depressive Disorder, Treatment-Resistant - drug therapy / Depressive Disorder, Treatment-Resistant - therapy / Disability / Drug delivery / Drugs / Glutamate receptors / Grants / Humans / Intervention / Lithium / Mental depression / Meta-analysis / N-Methyl-D-aspartic acid / Non-pharmacological intervention / Placebo effect / Psychiatry / Psychotherapy / Psychotropic drugs / Refractory depression / Review article / Systematic review / Therapy / Treatment methods / Treatment Outcome / Treatment outcomes / Treatment resistance